Overview

Neurodegeneration: A Growing Global Challenge Neurodegeneration is an irreversible process marked by the gradual loss of neuronal structure and function. With rising life expectancy worldwide, these conditions often manifest in middle to older adulthood are becoming an urgent health concern. Neurodegenerative disorders such as Alzheimer’s, Parkinson’s, Huntington’s disease, and Dementia cause progressive, irreversible damage to the brain and spinal cord, leading to symptoms like memory loss, cognitive decline, tremors, and impaired movement. While these conditions typically appear after age 60, genetic mutations can trigger early onset in some families, making family history a significant risk factor. Although there is no cure, treatments and interventions including medications, supportive therapies, and surgical options like deep brain stimulation can help manage symptoms.

Genetic testing plays a vital role in identifying individuals at increased risk, guiding treatment decisions, enabling psychosocial counseling, and supporting caregivers through informed planning. By uncovering the genetic basis of these disorders, we empower proactive care and personalized management. Harnessing cutting-edge Next-Generation Sequencing (NGS), the G2M panel analyzes a comprehensive set of genes linked to neurodegenerative disorders. These insights empower clinicians and patients to take proactive steps, enabling early risk detection, personalized prevention strategies, and tailored treatment plans. Knowing your genetic predisposition gives you a decisive advantage in safeguarding cognitive health and planning for the future.

The Genes2Me Alzheimer-Parkinson-Dementia NGS panel is a hybridization-based solution for targeted sequencing employing NGS. With a fast turnaround time, this product provides detection and identification of 139 clinically relevant genes spanning 0.4 Mb of genome size (whole coding sequence) that covers all major mutations like SNV, InDels, & CNV.